Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals' Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $407.1 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 5.36% year-over-year to $407.1 million in Q1 2026; TTM through Mar 2026 was $407.1 million, a 5.36% increase from a year earlier, with the FY2025 full-year figure at $428.3 million, up 17.99% from the prior year.
• Other Accumulated Expenses declined to $407.1 million in Q1 2026 per VRTX's latest filing, from $428.3 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $648.6 million in Q1 2024 and bottomed at $218.0 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $377.0 million (2023), against an average of $376.6 million.
• Across the five-year window, Other Accumulated Expenses surged 72.04% in 2024 and slumped 40.43% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $311.5 million in 2022, then jumped by 69.25% to $527.2 million in 2023, then sank by 31.15% to $363.0 million in 2024, then climbed by 17.99% to $428.3 million in 2025, then decreased by 4.95% to $407.1 million in 2026.
• Per Business Quant, the three latest VRTX Other Accumulated Expenses figures stand at $407.1 million (Q1 2026), $428.3 million (Q4 2025), and $441.5 million (Q3 2025).